eCPMV

**eCPMV** is an experimental intratumoral cancer immunotherapy composed of **empty cowpea mosaic virus capsids** that self-assemble into approximately 30 nm **virus-like particle nanoparticles** lacking viral nucleic acid. Developed by **Mosaic ImmunoEngineering**, it functions as an **in situ cancer vaccine** that activates innate immunity within the tumor microenvironment, with reported engagement of **Toll-like receptor 2** and **Toll-like receptor 4**, leading to recruitment and activation of neutrophils, dendritic cells, and downstream T-cell-mediated antitumor responses. The program has been investigated across multiple solid tumors, including glioblastoma, melanoma, ovarian cancer, and mammary tumors, with notable translational work in companion dogs with spontaneous cancers and a broader positioning as a local immunotherapy for solid tumors.

Other names

empty Cowpea Mosaic Viruscowpea mosaic virus-like particle